Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer.

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says.

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new stu ...

Daily low-dose aspirin reduced the risk for colorectal cancer recurrence by roughly half in patients with mutations in the ...

A randomized study has produced some hopeful news for colorectal cancer survivors with an unlikely suspect: the commonly used ...

Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on ...

Three-year results from the ALASCCA trial (NCT02647099), presented at the 2025 ASCO Gastrointestinal Cancer Symposium, showed ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...